187
Participants
Start Date
August 31, 2010
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg
Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukushima
GSK Investigational Site, Gunma
GSK Investigational Site, Hiroshima
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hyōgo
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ishikawa
GSK Investigational Site, Kagawa
GSK Investigational Site, Kagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kyoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Miyagi
GSK Investigational Site, Miyagi
GSK Investigational Site, Nagano
GSK Investigational Site, Nagano
GSK Investigational Site, Nagano
GSK Investigational Site, Nagano
GSK Investigational Site, Okayama
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Ōita
GSK Investigational Site, Ōita
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Toyama
GSK Investigational Site, Wakayama
GSK Investigational Site, Yamanashi
Lead Sponsor
GlaxoSmithKline
INDUSTRY